Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response.
J Biomol Struct Dyn
; 39(11): 4051-4065, 2021 Jul.
Article
in En
| MEDLINE
| ID: mdl-32448082
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Interleukin-13
/
Antibodies, Monoclonal
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Biomol Struct Dyn
Year:
2021
Document type:
Article
Affiliation country:
India
Country of publication:
United kingdom